Table 1.

Components of the Original Desirability of Outcome Ranking (DOOR) Endpoint and the CAMERA2 DOOR Endpoint

Component	Suggested Original DOOR Endpoint	CAMERA2 DOOR
Treatment failure	Lack of global resolution of infection at 8 weeks	Primary treatment failure defined as persistent bacteremia on day 5
Infectious complications	Development of drug resistance OR Newly identified metastatic focus of infection OR Persistent or resistant Staphylococcus aureus BSI	Secondary treatment failure defined as either microbiological relapse (positive blood culture at least 72 hours after blood cultures sterilization) OR microbiological treatment failure (new metastatic infection diagnosed after day 14)
Ongoing symptoms	Ongoing symptoms that limit daily activities, with or without evidence of ongoing infection	None available
Adverse events	Grade 4 adverse events	Any degree of AKI, regardless of the outcome or clinical relevance for the patient, OR any adverse reaction (adverse events thought to be related to study drugs as reported by trial investigators)
Death	At end of follow-up (8 weeks)	Until 90 days

Abbreviations: AKI, acute kidney injury; BSI, bloodstream infection; CAMERA2, Combination Antibiotics for MEthicillin Resistant Staphylococcus aureus; DOOR, desirability of outcome ranking.